Topic: inflammatory bowel disease
The EU approval is conditional on selling off a Shire experimental IBD drug, which Takeda said could attract "a number of potential buyers."
Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.
UCB is sponsoring an effort to create a clinical care standard for women with inflammatory bowel disease (IBD) before, during and after pregnancy.
Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.
The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.
A new disease awareness campaign from Daiichi Sankyo highlights iron deficits common in patients with Crohn’s disease and ulcerative colitis.
Takeda has rolled out Entyvio in multiple Asia-Pacific countries, but the Japanese drugmaker envisions even more growth in the region.
Takeda and Cedars Sinai researchers developed an online tool aimed at helping inflammatory bowel disease patients sort through available treatments.
Anti-TNFs have been running the table in inflammatory bowel disease, but that’s changing. And as it does, the market’s primed for a big expansion.
Takeda’s IBD awareness comic book campaign, a team-up with Marvel, ended with the Unbeatables prevailing over IBD—and evildoers, too.